English 
Deutsch 
Exton, PA—February 6, 2019—West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, and Swissfillon AG, a provider of aseptic fill and finish services to pharmaceutical and biotechnology companies, have commenced discussions that are intended to lead to a non-exclusive global collaboration to provide fill-finish capabilities to customersusing West’s proprietary SmartDose® drug delivery platform for complex molecules. West made the announcement at PharmaPack 2019, the annual conference for pharmaceutical packaging and drug delivery, held February 6-7 in Paris.
Through the collaboration, it is anticipated that West will be able to deliver an integrated solution with filled Daikyo Crystal Zenith® cartridges for the SmartDose wearable injector, which is expected to accelerate clinical development and enable customers to bring their innovative injectable drugs to market quickly. This new collaboration is expected to offer customers a robust clinical fill-finish capability later this year.
“We are very pleased to partner with Swissfillon delivery solution supporting our customers’ journey from molecule to market. It combines Swissfillon’sfill-finish expertise with West’s proprietary drug delivery technology to deliver a streamlined solution that meets the unique needs of pharmaceutical manufacturers around the world,” said Karen Flynn, SVP & Chief Commercial Officer, West.
“We are excited to work with West to bring our fill-finish capabilities to West’s SmartDose platformoffering,” said Daniel Kehl, Chief Executive Officer, Swissfillon AG. “We look forward to partneringtogether to support pharmaceutical and biotech customers to deliver innovative combination drugproducts to patients.”
Wearable drug delivery systems offer physicians having patients with chronic health conditions who require daily administration a reliable, convenient and easy to use method for home-based drug administration.
West’s SmartDose drug delivery platform enables patients to self-administer medication in accordance with their prescribed treatment. West developed the SmartDose platform with extensive human factors testing and analysis to understand the interaction between the patient and the delivery system. The SmartDose platform adheres to the patient’s body, usually on the abdomen, so patients can be hands- free during administration. The SmartDose platform is an integrated solution for the containment and delivery of injectable medications featuring a silicone-free Daikyo Crystal Zenith cartridge and a Flurotec® barrier film coated piston primary containment system.
Clinical fill-finish services are part of West’s new Integrated Solutions Program. The Program offers customers the opportunity to Simplify the JourneyTM from molecule to market with containment and delivery solutions for combination products; analytical testing services; regulatory support; and device manufacturing, assembly and drug handling designed for any stage of the drug development lifecycle.
For more information about West’s Integrated Solutions program, the SmartDose technology platform, or any of West’s technologies for integrated drug delivery, visit www.westpharma.com.
About Swissfillon AG
Swissfillon AG is an agile fill & finish contract manufacturing organization (CMO) for complex pharmaceutical and biopharmaceutical products. With its robot driven, fully automated filling line, Swissfillon provides highest quality and security drug product manufacturing services to its clients for clinical phase material to commercial supply. With its large inhouse knowledge in overall project management, compounding and filling technologies as well as quality assurance, Swissfillon is advising/supporting its clients to find and deliver fit-for-purpose solutions. Swissfillon is based in Visp, in the heart of the Swiss Alps.
Forward-Looking Statements
Certain forward-looking statements are included in this release. They use such words as “anticipated,” “will”, “deliver”, “enable”, “may,” “robust”, “accelerate,” “expected,” “look forward,” “ultimately,” and other similar terminology. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West’s partnership with Swissfillon will achieve any level of commercial success related to its SmartDose® drug delivery platform or that the Integrated Solutions program will lead to any particular result. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customer’s changing inventory requirements and manufacturing plans; customer decisions to move forward with the new capability being offered through our partnership with Swissfillon; dependence on third-party suppliers and partners; and interruptions or weaknesses in our supply chain. This list of important factors is not all inclusive. For a description of certain additional factors that could cause West’s future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled „Risk Factors,“ in West’s Annual Report on Form 10-K for the year ended December 31, 2017. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world’s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West’s 2017 net sales of $1.6 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
FluroTec® and Simplify the JourneyTM are trademarks and registered trademarks of West PharmaceuticalServices, Inc., in the United States and other jurisdictions. FluroTec® technology is licensed from Daikyo Seiko, Ltd.
SmartDose® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.
Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith® and Flurotec technology are licensed from Daikyo Seiko, Ltd.
###
Media Contact:
Emily Denney
Vice President, Global Communications
+1-610-594-3035
Emily.Denney@westpharma.com
